论文部分内容阅读
目的探讨喜炎平联合重组人干扰素α-1b治疗小儿手足口病临床疗效。方法 156例患儿随机分为两组,两组均给予常规治疗,对照组静脉点滴病毒唑注射液,治疗组静脉滴注喜炎平注射液,肌肉注射重组人干扰素α-1b,观察疗效。结果治疗组总有效率93.6%,对照组总有效率71.8%,治疗组疗效明显优于对照组(P<0.05)。治疗组退热时间、皮疹消退时间明显早于对照组(P<0.05)。结论喜炎平联合重组人干扰素α-1b治疗小儿手足口病疗效明显,不良反应少,值得推广。
Objective To investigate the clinical efficacy of Xiyanping combined with recombinant human interferon α-1b in the treatment of hand-foot-mouth disease in children. Methods 156 cases of children were randomly divided into two groups, both groups were given conventional treatment, the control group intravenous injection of ribavirin, the treatment group intravenous injection of Xiyan Ping, intramuscular injection of recombinant human interferon alpha-1b, to observe the effect . Results The total effective rate was 93.6% in the treatment group and 71.8% in the control group. The curative effect in the treatment group was significantly better than that in the control group (P <0.05). Treatment group antipyretic time, rash subsided time was significantly earlier than the control group (P <0.05). Conclusion Xiyanping combined with recombinant human interferon α-1b treatment of children with hand-foot-mouth disease obvious effect, less adverse reactions, it is worth promoting.